Mineralocorticoid receptor antagonists

Hari Krishnan Parthasarathy; Thomas M MacDonald

doi:10.1007/s11906-007-0009-3

Mineralocorticoid receptor antagonists

Curr Hypertens Rep. 2007 Mar;9(1):45-52. doi: 10.1007/s11906-007-0009-3.

Authors

Hari Krishnan Parthasarathy¹, Thomas M MacDonald

Affiliation

¹ Hypertension Research Centre, Division of Medicine & Therapeutics, Ninewells Hospital & Medical School, University of Dundee, Dundee, Scotland, DD1 9SY, UK.

PMID: 17362671
DOI: 10.1007/s11906-007-0009-3

Abstract

With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.

Publication types

Review

MeSH terms

Animals
Canrenoic Acid / pharmacology
Canrenoic Acid / therapeutic use
Cardiovascular Diseases / drug therapy
Eplerenone
Humans
Mineralocorticoid Receptor Antagonists* / adverse effects
Mineralocorticoid Receptor Antagonists* / pharmacology*
Mineralocorticoid Receptor Antagonists* / therapeutic use*
Renin-Angiotensin System / drug effects
Spironolactone / analogs & derivatives
Spironolactone / pharmacology
Spironolactone / therapeutic use

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone
Canrenoic Acid